ABUS vs MRNA
ABUS: A clinical-stage biopharmaceutical company developing novel treatments for chronic hepatitis B while generating value from its lipid nanoparticle drug delivery patent portfolio. MRNA: Moderna is a pioneer in mRNA technology, working to transform medicine by developing a broad pipeline of prophylactic vaccines and therapeutic medicines.
Side-by-side fundamentals
| Metric | ABUS | MRNA | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $4.33 | $242.08 | |
| Market cap | $857M | $96.6B | |
| P/E as of 2026-10-20 | 5.48 | n/a | |
| Net margin FY2025, SEC XBRL | -237.9% | -145.2% | MRNA higher |
| Operating margin FY2025, SEC XBRL | -271.0% | -158.1% | MRNA higher |
| ROE FY2025, SEC XBRL | -43.7% | -32.6% | MRNA higher |
| ROA FY2025, SEC XBRL | -35.4% | -22.9% | MRNA higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.00 | 0.09 | ABUS lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +128.2% | -39.9% | ABUS higher |
| Revenue CAGR (3y) SEC XBRL | -28.8% | -53.4% | ABUS higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.95 | 1.41 | |
| 1-year return as of 2026-10-20 close | -4.8% | +788.7% | MRNA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.